The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001214325
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
23/09/2025
Date registered
Help: Date registered
1/10/2026
Date last updated
Help: Date last updated
1/10/2026
Date data sharing statement initially provided
Help: Data sharing statement date
1/10/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
A study to investigate safety, and pharmacokinetics, of single
(SAD) and multiple (MAD) ascending doses of GE8820 in healthy adults
Scientific title
A randomized, placebo-controlled, single and multiple ascending dose study of
the safety and pharmacokinetics of intravenous and subcutaneous
administration of GE8820 in healthy adults
Additional trial identifiers [1] 315278 0
GE8820-001
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Autoimmune diseases 338731 0
Condition category
Condition code
Skin 335031 335031 0 0
Dermatological conditions

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This is a randomized, double-blind (participant and clinical assessor-blinded; sponsor open), placebo-controlled study in healthy adults to evaluate the safety and pharmacokinetics of GE8820 after single and multiple doses administered by intravenous infusion or subcutaneous injection. An additional 3 cohorts for Part A and 5 cohorts for Part B may be added to the study based on decisions from the safety review committee. Dose levels for the additional cohorts will not exceed 60 mg/kg.

Part A (Single Ascending Dose): Participants in Cohorts 1 to 5 will receive a single IV dose and participants in Cohort 6 will receive a single SC flat dose. Each cohort will enroll 4 participants receiving GE8820 and 2 receiving placebo (2:1 randomisation). Doses levels will start from 1 mg/kg and maximum of 60 mg/kg each cohort dose level will be confirmed by a safety review committee. Participants will be followed from screening through Day 29. All doses are administered by clinic staff under direct supervision.

Part B (Multiple Ascending Dose): Participants will receive repeat doses of GE8820 or placebo via IV and SC over a period of up to 29 days with doses not to exceed those in Part A. Dose frequencies will be weekly or 3 days apart, and then weekly, depending on the cohort and the decisions of the safety review committee. Participants will be followed weekly for 28 days after the final dose. All doses are administered by clinic staff under direct supervision. Doses levels will start from 1 mg/kg and maximum of 60 mg/kg each cohort dose level will be confirmed by a safety review committee
Intervention code [1] 331881 0
Treatment: Drugs
Description of the comparator or control
Participants in the control arm will receive a matching placebo (0.9% normal saline) administered by the same route and on the same schedule as the active GE8820 treatment for each cohort.
Control group
Placebo

Outcomes
Primary outcome [1] 342653 0
Incidence of treatment-emergent adverse events (AEs) in both Part A and Part B of the study.
Timepoint [1] 342653 0
From first dose (Day 1) through 28 days after the last dose (End of Study).
Primary outcome [2] 342654 0
Changes in vital signs, ECGs, and physical examination findings (composite safety outcome assessed as part of overall safety evaluation for both Part A and Part B).
Timepoint [2] 342654 0
From screening through End of Study, including pre- and post-dose assessments on dosing days and scheduled follow-up visits (up to Day 29 for Part A; up to 28 days after last dose for Part B).
Primary outcome [3] 342655 0
Changes in clinical laboratory parameters (hematology, clinical chemistry including liver and renal function tests, metabolic panel, and urinalysis) will be assessed as a composite primary outcome for both Part A and Part B of the study.
Timepoint [3] 342655 0
From screening through End of Study, including baseline, dosing days, and scheduled follow-up visits up to Day 29 (Part A) or 28 days after last dose (Part B).
Secondary outcome [1] 451712 0
Change in pharmacokinetic parameters of GE8820 will be assessed as a composite secondary outcome for both Part A and Part B of the study.
Timepoint [1] 451712 0
PK samples will be collected from Day 1 through Day 29 in Part A, and from Day 1 through up to 28 days after the last dose in Part B (approximately Day 57).
Secondary outcome [2] 451713 0
Change in circulating IgG4 levels over time.
Timepoint [2] 451713 0
From baseline through Day 29 (Part A) and from baseline through 28 days after last dose (Part B), with serial sampling on dosing and follow-up days.

Eligibility
Key inclusion criteria
1. Overtly healthy, per Investigator assessment (history, physical exam, labs, cardiac monitoring).
2. Body weight 40–120 kg; BMI 18.5–32 kg/m².
3. Males or females of child-bearing potential and with risk of pregnancy must use highly effective contraception from Day 1 until -1 month post-last dose.
Minimum age
18 Years
Maximum age
64 Years
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
1. Clinically significant infection, malignancy, or cardiovascular, hematological, renal, hepatic, pulmonary, endocrine, GI, immunological, dermatological, neurological, or psychiatric disease, or surgical history that may interfere with study conduct/interpretation or increase risk (per Investigator).
2. Allergic or inflammatory diseases including history of desensitization therapy.
3. Febrile illness within 14 days prior to Day –1.
4. Positive urine drug screen at Screening or on Day -1. Note that casual smoking (5 cigarettes per week), positive cotinine, or positive tetrahydrocannabinol (THC) on drug screen are not exclusionary.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
The method of concealment involves the pharmacy being unblinded and allocating the treatment assignment based on a randomisation list.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
Intervention assignment
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD

Funding & Sponsors
Funding source category [1] 319848 0
Commercial sector/Industry
Name [1] 319848 0
GlycoEra AG
Country [1] 319848 0
Switzerland
Primary sponsor type
Commercial sector/Industry
Name
GlycoEra AG
Address
Country
Australia
Secondary sponsor category [1] 322372 0
None
Name [1] 322372 0
Address [1] 322372 0
Country [1] 322372 0
Other collaborator category [1] 283642 0
Commercial sector/Industry
Name [1] 283642 0
Novotech Pty Ltd
Address [1] 283642 0
Country [1] 283642 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 318404 0
Alfred Hospital Ethics Committee
Ethics committee address [1] 318404 0
Ethics committee country [1] 318404 0
Australia
Date submitted for ethics approval [1] 318404 0
06/08/2025
Approval date [1] 318404 0
28/08/2025
Ethics approval number [1] 318404 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 144078 0
Dr Gloria Wong
Address 144078 0
Nucleus Network, Level 5, Burnet Tower, 89 Commercial Road, Melbourne Victoria 3004.
Country 144078 0
Australia
Phone 144078 0
+61 0737072720
Fax 144078 0
Email 144078 0
Contact person for public queries
Name 144079 0
Merylyn Ryan
Address 144079 0
Nucleus Network Brisbane Level 5, 300C Herston Road, Herston, QLD 4006
Country 144079 0
Australia
Phone 144079 0
+61 3 9491 8563
Fax 144079 0
Email 144079 0
Contact person for scientific queries
Name 144080 0
Merylyn Ryan
Address 144080 0
Nucleus Network Brisbane Level 5, 300C Herston Road, Herston, QLD 4006
Country 144080 0
Australia
Phone 144080 0
+61 3 9491 8563
Fax 144080 0
Email 144080 0

Data sharing statement
Will the study consider sharing individual participant data?
No



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.